Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Multicenter, Randomized, Open-label, Phase 3 Trial Comparing Selpercatinib to Physicians Choice of Cabozantinib or Vandetanib in Patients With Progressive, Advanced, Kinase Inhibitor Naïve, RET-Mutant Medullary Thyroid Cancer (LIBRETTO-531)

Trial Profile

A Multicenter, Randomized, Open-label, Phase 3 Trial Comparing Selpercatinib to Physicians Choice of Cabozantinib or Vandetanib in Patients With Progressive, Advanced, Kinase Inhibitor Naïve, RET-Mutant Medullary Thyroid Cancer (LIBRETTO-531)

Status: Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 06 Feb 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Selpercatinib (Primary) ; Cabozantinib; Vandetanib
  • Indications Medullary thyroid cancer; Thyroid cancer
  • Focus Registrational; Therapeutic Use
  • Acronyms LIBRETTO-531
  • Sponsors Eli Lilly and Company; Eli Lilly and Company (India) Pvt. Ltd; Loxo Oncology

Most Recent Events

  • 04 Feb 2025 The protocol has been amended change in time frame.
  • 04 Feb 2025 Planned End Date changed from 28 Feb 2026 to 1 Feb 2026.
  • 23 May 2024 According to an Eli Lilly and Company media release, data from this trial will be presented at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting taking place May 31 - June 4 in Chicago.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top